R
Replenish
Drug delivery devices to treat ophthalmic diseases the
About Replenish
Replenish, Inc. was a medical device company established in 2007, operating from Pasadena, California, before being acquired by Alcon in 2014. The firm focused on developing a solution for chronic eye diseases, such as wet age-related macular degeneration (AMD) and diabetic macular edema, which traditionally require patients to endure frequent and uncomfortable injections. One of the co-founders, Dr. Mark S. Humayun, an accomplished inventor and researcher, was pivotal in the company's mission to create a more effective drug administration route for the eye.
The company's core product was the MicroPump, an implantable and refillable drug delivery system. This device was engineered to be surgically placed under the skin of the eye in a short outpatient procedure. Once implanted, the pump could be wirelessly programmed and recharged by a physician to deliver nanoliter-sized doses of medication at predetermined intervals—be it hourly, daily, or monthly. This automated delivery mechanism was intended to replace the standard regimen of physician-administered syringe injections that many patients undergo for life. The MicroPump's reservoir was designed to hold enough medication for up to six months before needing a refill, significantly reducing the treatment burden for patients.
Replenish's business model centered on the development and eventual sale of this therapeutic device within the multi-billion dollar retinal therapeutic market. The company was venture-backed, having raised $10.2 million in an early-stage VC round in July 2009 with investors including Collaborative Fund. Human trials for the MicroPump were conducted to test its safety and efficacy. A study involving patients with diabetic macular edema demonstrated the device's safety over a 90-day period and its ability to deliver programmed microdoses into the vitreous cavity. While some trials were successful, others faced challenges with dose delivery. Ultimately, Replenish, Inc. was acquired by Alcon on January 1, 2014.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Pasadena, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 64.2/100
- Industry
- Health, Transportation
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Jul 2009 | $10M | $41M | Undisclosed | — |
| SPINOUTOther financing | Jan 2007 | $0 | — | Caltech, California Institute of Technology | — |
Growth signals
Latest recorded traffic for Replenish is 120 monthly website visits, down 60% over the last three months. Replenish's team declined 10% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
Caltech, California Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Replenish on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Replenish’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







